Related by context. All words. (Click for frequent words.) 79 Bevacizumab 78 Dasatinib 76 Voreloxin 75 Trastuzumab 75 Lenalidomide 74 Pemetrexed 74 Perifosine 74 Monotherapy 74 Meets Primary Endpoint 74 Irinotecan 74 VAPRISOL 74 Cisplatin 74 erlotinib Tarceva ® 74 Aflibercept 73 Xanafide 73 Erlotinib 73 Capecitabine 73 Well Tolerated 73 Antitumor Activity 73 Anti Tumor 73 Antiangiogenic 73 Fludarabine 73 PEGylated Fab fragment 73 proteasome inhibitor 73 Gemcitabine 73 Glufosfamide 72 Eltrombopag 72 Fulvestrant 72 Randomized Phase 72 sorafenib Nexavar 72 Aliskiren 72 Phase 2b Clinical Trial 72 Dapagliflozin 72 Pioglitazone 72 Pegylated Liposomal Doxorubicin 72 pan HDAC inhibitor 72 INCB# [001] 72 Epratuzumab 72 Peginterferon 72 decitabine 72 Previously Treated 72 dasatinib Sprycel ® 72 Rituximab 72 HuMax CD4 72 Interferon Beta 72 Tezampanel 72 Methylnaltrexone 72 BAY #-# 72 Boceprevir 71 Natalizumab 71 Hormone Refractory Prostate Cancer 71 Imatinib 71 alpha 2a 71 DOXIL 71 Metastatic Melanoma 71 Nilotinib 71 oral prodrug 71 sodium glucose cotransporter 71 Gefitinib 71 Receptor Antagonists 71 Liposomal 71 Tanespimycin 71 Doxorubicin 71 Traficet EN 71 Gemzar ® 71 thalidomide Thalomid 71 Anti Tumor Activity 71 Alemtuzumab 71 TNF Tumor Necrosis Factor 71 receptor tyrosine kinase inhibitor 71 Vaprisol 71 Aurora Kinase 71 idarubicin 71 Relapsed Refractory Multiple Myeloma 71 Tumor Necrosis Factor 71 Phase 2b Study 71 Ofatumumab 71 alkylating agent 71 Carfilzomib 71 Etanercept 71 HER2 positive metastatic breast 71 gemcitabine Gemzar 71 5 Fluorouracil 71 liposomal formulation 71 tyrosine kinase inhibitor 71 Peginterferon Alfa 2a 71 Phase 2a Clinical Trial 71 MGCD# [001] 71 Pertuzumab 71 Cyclophosphamide 71 Pharmacokinetic Study 71 Panzem R NCD 71 somatostatin analogue 71 Renal Cell Carcinoma 71 PXD# 70 Pegylated 70 Romidepsin 70 Hsp# Inhibitor 70 Amrubicin 70 Antiviral Activity 70 Phase IIb Trial 70 Decitabine 70 gefitinib Iressa 70 Blinatumomab 70 Panzem R 70 HDAC Inhibitor 70 Phase 2b Trial 70 DFMO 70 sorafenib tablets 70 Golimumab 70 Linaclotide 70 YONDELIS 70 Doxil ® 70 Sapacitabine 70 bortezomib Velcade 70 Pralatrexate 70 selective modulator 70 Melphalan 70 PKC# 70 Docetaxel 70 cetuximab Erbitux R 70 bevacizumab Avastin ® 70 vorinostat 70 Vandetanib 70 proteasome inhibitors 70 Degarelix 70 Paraplatin ® 70 Prolongs Survival 70 orally administered inhibitor 70 Everolimus 70 Tocilizumab 70 biologic therapy 70 Anti TNF 70 tolvaptan 70 Daclizumab 70 Lubiprostone 70 Telbivudine 70 Dalbavancin 70 Granulocyte Colony Stimulating Factor 70 ganetespib 70 Clinical Trial Results 70 bevacizumab Avastin 70 Eculizumab 70 Metastatic Colorectal Cancer 70 Preclinical Data 70 Pathway Inhibitor 70 EGFr 70 humanized anti 70 Tipranavir 70 Ixabepilone 70 Tyrosine Kinase Inhibitor 70 Phase IIb Clinical Trial 70 HGS ETR2 70 Seliciclib 70 Bosentan 70 Trabectedin 69 IL# PE#QQR 69 Neulasta ® 69 Carboplatin 69 Survival Benefit 69 Tamibarotene 69 Sipuleucel T 69 Pivotal Phase III 69 JAK Inhibitor 69 Cutaneous T 69 polymerase inhibitor 69 Ranolazine 69 Velcade bortezomib 69 Investigational Agent 69 Chronic Lymphocytic Leukemia CLL 69 azacytidine 69 Talabostat 69 imatinib Gleevec 69 Elesclomol 69 Metastatic Renal Cell Carcinoma 69 Oral Fingolimod 69 IFN α 69 OXi# 69 Azacitidine 69 MGd 69 pharmacokinetic interactions 69 Pivotal Phase 69 HGS ETR1 69 KRN# 69 dacarbazine 69 Exemestane 69 Diabetic Nephropathy 69 XYOTAX TM 69 peripherally acting 69 pegylated liposomal doxorubicin 69 alfa 2a 69 tocilizumab 69 galiximab 69 Anthracycline 69 bleomycin 69 PEG IFN 69 targeting CD# 69 CCX# 69 Solid Tumors 69 mTOR inhibitor 69 selective inhibition 69 MEK inhibitor 69 Tacrolimus 69 Drug Candidate 69 IFN beta 69 Neoadjuvant 69 mycophenolate mofetil 69 Pharmacokinetics PK 69 Vorinostat 69 Cloretazine ® 69 ZOLINZA 69 Fondaparinux 69 Tolvaptan 69 Maribavir 69 Treated Patients 69 EGFR TKI 69 Omacetaxine 69 interferon IFN 69 pertuzumab 69 erlotinib Tarceva 69 xanthine oxidase inhibitor 69 Androgen Receptor 69 leukemia CLL 69 Oritavancin 69 Dendritic Cells 69 bendamustine 69 Mipomersen 69 Mitoxantrone 69 HuMax CD# 69 AEG# 69 icatibant 69 anti angiogenic agent 69 Valsartan 69 PEGylated anti 69 Glatiramer Acetate 69 Newly Diagnosed Multiple Myeloma 69 CD# monoclonal antibody 69 Nucleoside 69 Tiotropium 69 ara C 69 Relapsing Multiple Sclerosis 69 LHRH 69 Nexavar ® 69 Gleevec resistant 69 imatinib Gleevec ® 69 MEK Inhibitor 69 Bosutinib 69 Naive Patients 69 nucleoside analog 69 TLK# 69 Radioimmunotherapy 69 FOLFOX6 69 HSP# inhibitor 68 Relapsed Refractory 68 Copegus ribavirin 68 Cethromycin 68 Leukine ® 68 Recombinant Human 68 fosbretabulin 68 dasatinib Sprycel 68 angiogenesis inhibitor 68 Epidermal Growth Factor Receptor 68 Chemokine Receptor 68 Tyrima 68 trabectedin 68 Lacosamide 68 depsipeptide 68 sunitinib Sutent ® 68 Temsirolimus 68 TREANDA 68 Vidaza azacitidine 68 gemcitabine Gemzar ® 68 LY# [003] 68 Interferon alfa 68 Taxotere ® 68 Metastatic Prostate Cancer 68 Ambrisentan 68 Tesetaxel 68 ixabepilone 68 Ecallantide 68 CA4P 68 adalimumab Humira 68 mapatumumab 68 Kinase Inhibitor 68 cediranib 68 Hycamtin 68 investigational humanized monoclonal antibody 68 CIMZIA TM 68 Unresectable 68 Randomized Double blind 68 estramustine 68 Myelodysplastic Syndromes 68 elotuzumab 68 pomalidomide 68 molecularly targeted 68 Advanced Renal Cell 68 Pulmonary Arterial Hypertension 68 Myelodysplastic Syndrome MDS 68 Fluorouracil 68 Complicated Skin 68 orally bioavailable 68 Chronic Hepatitis C 68 small molecule Hedgehog 68 Tigecycline 68 CD3 monoclonal antibody 68 Investigational Drug 68 TYKERB 68 Raltegravir 68 APTIVUS r 68 alefacept 68 metastatic malignant 68 FOLFIRI 68 Elvitegravir 68 HuMax EGFr 68 Iloperidone 68 Calcitonin 68 antimetabolite 68 Advanced Melanoma 68 cytostatic 68 Factor VIIa 68 GW# [003] 68 Low Dose 68 II Clinical Trial 68 CYC# 68 EOquin TM 68 cell lymphoma CTCL 68 Pazopanib 68 metastatic renal cell carcinoma 68 MAGE A3 ASCI 68 generation purine nucleoside 68 Darunavir 68 dexpramipexole 68 Initiate Phase 68 ibritumomab tiuxetan 68 Elotuzumab 68 TAXOTERE R 68 Platinol ® 68 CDK inhibitor 68 Panitumumab 68 CD# antibody [001] 68 ceftazidime 68 Adjuvant Treatment 68 SPRYCEL ® 68 daunorubicin 68 Combination Therapy 68 Pegylated Interferon 68 selective androgen receptor modulator 68 Adalimumab 68 Phase III Clinical Trial 68 Sym# 68 Bendamustine 68 tanespimycin 68 Orally administered 68 5 HT6 receptor 68 Aptivus ® 68 Immunogenic 68 posaconazole 68 Investigational Compound 68 Unfractionated Heparin 68 panobinostat 68 platelet inhibitor 68 trans retinoic acid 68 Patients Treated With 68 Humanized Anti 68 Zoledronic Acid 68 docetaxel chemotherapy 68 Zolinza 68 AKT inhibitor 68 amprenavir 68 insulin sensitizing 68 meropenem 68 Novel Inhibitor 68 anakinra 68 Previously Untreated 68 mertansine 68 Bavituximab 68 IAP inhibitors 68 NDA Submission 68 fulvestrant 68 azacitidine 68 docetaxel Taxotere ® 68 Dose Escalation 68 Soft Tissue Sarcoma 68 luteinizing hormone releasing 68 Telaprevir 68 AMN# [001] 68 SCH # 67 visilizumab 67 Aurora kinase 67 sipuleucel T 67 endothelin receptor antagonists 67 Dose Ranging Study 67 efalizumab 67 Interferon Alfa 67 Placebo Controlled Trial 67 protein kinase inhibitor 67 Phase 2a Trial 67 Telmisartan 67 leukemia AML 67 5alpha reductase 67 octreotide acetate 67 trastuzumab Herceptin 67 Immunomodulatory 67 EGFR inhibitors 67 Phase III Trials 67 Study Evaluating 67 Ibritumomab Tiuxetan 67 Camptosar ® 67 mecamylamine 67 Moxifloxacin 67 Bivalirudin 67 Investigational Treatment 67 Sulfonylurea 67 Malignant Glioma 67 Romiplostim 67 Cytarabine 67 metaglidasen 67 bortezomib Velcade R 67 Double Blind Placebo 67 Demonstrates Potent 67 temsirolimus 67 INTEGRILIN R 67 immunomodulator 67 nilotinib 67 nab paclitaxel 67 sorafenib Nexavar ® 67 dasatinib 67 Fludara 67 trastuzumab Herceptin R 67 Ustekinumab 67 bevacizumab Avastin R 67 evaluating tivozanib 67 Lamivudine 67 administered subcutaneously 67 XL# XL# 67 gastrointestinal stromal tumors GIST 67 Anticancer Compound 67 Belimumab 67 Diffuse Large B 67 Ceftaroline 67 zoledronate 67 refractory chronic lymphocytic 67 Lenocta 67 Ribavirin 67 INCB# [003] 67 oral proteasome inhibitor 67 ACE Inhibitors 67 paclitaxel Taxol 67 Relapsed 67 Denufosol 67 Laquinimod 67 vWF 67 Symadex 67 immunomodulatory therapy 67 nucleoside reverse transcriptase inhibitor 67 administered concomitantly 67 Hepatocellular Carcinoma 67 Clofarabine 67 Castration Resistant Prostate Cancer 67 CYT# potent vascular disrupting 67 Cytotoxic 67 alvespimycin 67 Cytotoxicity 67 selective antagonist 67 Teriflunomide 67 proteasome inhibitor bortezomib 67 Fluconazole 67 Tolerability 67 Pooled Analysis 67 histone deacetylase inhibitor 67 Medoxomil 67 ribavirin RBV 67 6R BH4 67 Phase III Trial 67 receptor blocker 67 antiangiogenic 67 Peg IFN 67 IMC A# 67 GSK# [001] 67 PNP inhibitor 67 ZD# [001] 67 Inhalation Solution 67 Adefovir 67 Squalamine 67 antiplatelet agent 67 AEGR 67 substrates inhibitors 67 N methyl 67 Leukine 67 ISTODAX 67 APTIVUS 67 PEG SN# 67 mesylate 67 Safinamide 67 Clevudine 67 Advanced Colorectal Cancer 67 T#I [002] 67 Bezielle 67 lapatinib Tykerb 67 nucleoside 67 Refractory Hodgkin Lymphoma 67 AZT zidovudine Retrovir 67 anticancer compound 67 Antitumor 67 Estrogen Receptor 67 standard chemotherapy regimen 67 EZN 67 Ocrelizumab 67 IAP inhibitor 67 vascular disrupting agent 67 generation antisense inhibitor 67 ENMD # 67 Presents Preclinical Data 67 vascular disrupting agents 67 PLX# 67 Archexin 67 vandetanib 67 Mycophenolate Mofetil 67 Immunosuppression 67 RAV# 67 Radezolid 67 Single Dose 67 Long Term Efficacy 67 Anidulafungin 67 refractory cutaneous T 67 2 methoxyestradiol 67 targeted radiotherapeutic 67 mGluR5 NAM 67 PSN# [002] 67 Disease Progression 67 TELINTRA 67 #ME# 67 HDACi 67 Novel Antibiotic 67 Octreotide 67 TAFA# 67 vinca alkaloid 67 Sevelamer 67 nilotinib Tasigna ® 67 Adjuvant Chemotherapy 67 Ziprasidone 67 XmAb# 67 Phase III Pivotal 67 Plus Ribavirin 67 MyVax R 67 immune modulatory 67 Adjuvant Therapy 67 Varespladib 67 DAVANAT 67 itraconazole 67 PSMA ADC 67 Ozarelix 67 angiotensin receptor blocker ARB 67 BRIM2 67 microtubule targeting 67 Ticagrelor 67 dexamethasone Decadron 67 non nucleoside inhibitor 67 Novel Oral 67 interferon alfa 67 lenalidomide Revlimid R 67 Vidofludimus 67 Tarvacin 67 Abatacept 67 PRT# 67 VEGF inhibitors 67 ADP receptor antagonist 67 glatiramer acetate 67 Hydroxyurea 67 Receptor Agonist 67 cilengitide 67 Pafuramidine 67 Herceptin trastuzumab 67 sitaxsentan 67 BAL# [002] 66 class anticancer quinolone 66 abatacept Orencia 66 cetuximab Erbitux ® 66 MEK inhibitors 66 orally dosed 66 DORIBAX 66 Cyclosporine 66 metformin sulfonylurea 66 subcutaneously administered 66 Efficacy Trial 66 Aplidin R 66 Aptamer 66 rituximab 66 FLT3 66 Chronic Myeloid Leukemia 66 histone deacetylase HDAC inhibitor 66 Intravesical 66 Arimoclomol 66 Preclinical Study 66 SGLT2 66 anticancer agent 66 LT NS# 66 Diabetic Neuropathy 66 mRCC 66 Cannabinor 66 gemcitabine cisplatin 66 Demonstrated Significant 66 Personalized Immunotherapy 66 Chronic Lymphocytic Leukemia 66 superficial bladder cancer 66 Toxicities 66 Antisense 66 Parathyroid Hormone 66 relapsed MM 66 PD LID 66 Darusentan 66 multikinase inhibitor 66 Chemoradiation 66 OMP #M# 66 Infliximab 66 insulin sensitizers 66 FASLODEX 66 ALK inhibitor 66 infliximab Remicade 66 rituximab Rituxan 66 tigecycline 66 Elagolix 66 AP# [003] 66 Tumor Response 66 Antitumor activity 66 signal transduction inhibitor 66 pegylated interferons 66 Omacetaxine mepesuccinate 66 D aspartate NMDA receptor 66 Xeloda ® 66 sunitinib malate 66 Enoxaparin 66 antidiabetic 66 familial amyloidotic polyneuropathy FAP 66 Ridaforolimus 66 Relapsed Multiple Myeloma 66 Cholinesterase Inhibitors 66 LEP ETU 66 beta 1a 66 Potent Anti 66 RAPAFLO 66 Cyclooxygenase 2 66 Dose Escalation Study 66 Chemophase 66 Palifosfamide 66 Enzyme Replacement Therapy 66 Abiraterone Acetate 66 Lupus Nephritis 66 cinacalcet 66 thymalfasin 66 FUSILEV enhances 66 Ceflatonin 66 protein tyrosine phosphatase 1B 66 INC# 66 sunitinib Sutent 66 See CLINICAL PHARMACOLOGY 66 Cloretazine 66 prucalopride 66 direct thrombin inhibitors 66 Mg Uk 66 Tasimelteon 66 Small Molecule 66 Lamotrigine 66 Pivotal Study 66 docetaxel Taxotere R 66 Avanafil 66 Proxinium TM 66 pegfilgrastim 66 Autologous Stem Cell Transplantation 66 First Patient Dosed 66 relapsed ovarian cancer 66 Cytochrome P# 66 Methotrexate 66 Taxane 66 LY# [002] 66 Milatuzumab 66 Study Showed 66 Receptor Antagonist 66 Incretin 66 amrubicin 66 Targretin 66 Posaconazole 66 OMP #R# 66 Darinaparsin 66 relapsed multiple myeloma 66 Icatibant 66 IFN alpha 66 LHRH agonists 66 Replacement Therapy 66 huC# DM4 66 Alocrest 66 FOLOTYN ® 66 chemopreventive agent 66 mGluR5 negative 66 Kahalalide F 66 Insulin Glargine 66 Rigel R# 66 tenofovir Viread 66 generation Hsp# inhibitor 66 teriflunomide 66 Paclitaxel 66 Mg Usa 66 cidofovir 66 Immunotherapeutic 66 Plicera 66 alpha folate receptor 66 Is Well Tolerated 66 SYN# 66 Novel Mechanism 66 Progenitor Cells 66 antibody MAb 66 Deforolimus 66 ELACYT 66 DU #b 66 raltegravir 66 anti CD3 66 RhuDex ® 66 entinostat 66 DAPT 66 Cloretazine R VNP#M 66 Cinacalcet 66 Combination therapy 66 rNAPc2 66 Efficacious 66 Interferon beta 1a 66 Enzastaurin 66 Celecoxib 66 enzyme inhibitor 66 Anti VEGF 66 alpha 2b 66 ORENCIA ® 66 CYP#A# CYP#D# 66 interferon gamma 1b 66 Anti Angiogenic 66 docetaxel Taxotere 66 interferon alfa 2b 66 intravenously administered 66 intravesical infusion therapy 66 OncoVEX GM CSF 66 anticancer therapy 66 seliciclib 66 Civacir 66 Plaque Psoriasis 66 PEGylated 66 radiation sensitizer 66 huN# DM1 66 Prodrug 66 tafamidis 66 MNTX 66 Antigen Specific 66 HuLuc# 66 HMG CoA reductase inhibitor 66 myelofibrosis polycythemia vera 66 Kinase Inhibitors 66 Azedra 66 Erythropoietin 66 Severe Sepsis 66 CoFactor 66 PegIFN RBV 66 Apaziquone 66 Oral Formulation 66 Imprime PGG 66 Tasigna nilotinib 66 candesartan cilexetil 66 chemotherapeutic agent 66 pegylated 66 Annamycin 66 Guanilib 66 Otelixizumab 66 CTAP# Capsules 66 Candesartan 66 PDE4 inhibitor 66 NMDA antagonist 66 PEG interferon 66 virus HCV protease inhibitor 66 Systemic Delivery 66 gefitinib 66 Nitazoxanide 66 JAK2 Inhibitor 66 ritonavir boosted 66 Monoclonal Antibody 66 novel VDA molecule 66 hypoxia inducible factor 66 Sorafenib 66 TORISEL 66 bortezomib 66 Ranibizumab 66 humanized antibody 66 chemotherapeutic drug 66 Preclinical studies suggest 66 dopamine partial agonist 66 Cardiotoxicity 66 interferon therapy 66 Teriparatide 66 TACI Ig 65 Cloretazine VNP#M 65 Atypical Hemolytic Uremic Syndrome 65 E1 INT TM 65 Oral Anticoagulant 65 Combination Treatment 65 riociguat 65 Allogeneic 65 targeted antifolate 65 Patients Receiving 65 mTOR mammalian target 65 Cetrorelix 65 Navelbine ® 65 Fludara ® 65 Aripiprazole 65 cytotoxic chemotherapy 65 imatinib resistant 65 Epoetin Alfa 65 abacavir Ziagen 65 Azathioprine 65 immunomodulatory 65 Improves Survival 65 Apixaban 65 castration resistant prostate cancer 65 angiotensin II receptor blocker 65 liposomal doxorubicin 65 octreotide 65 Taxol ® 65 JAK1 65 Improved Survival 65 AGILECT R 65 Fluticasone 65 Myelofibrosis 65 TYZEKA 65 paricalcitol 65 5 FU leucovorin 65 gemcitabine 65 nicardipine 65 vidofludimus 65 Rasagiline 65 Vitro Activity 65 inhibitor RG# 65 Vidaza ® 65 Dacogen decitabine 65 DXL# 65 eniluracil 65 amphotericin B 65 Pegasys ® 65 nucleoside analogues 65 irreversible inhibitor 65 PRTX 65 Bafetinib 65 HCV protease 65 perifosine 65 OPAXIO 65 Potent Inhibitor 65 GAMMAGARD LIQUID 65 investigational monoclonal antibody 65 small molecule thrombopoietin 65 Itraconazole 65 Investigational Oral 65 dependent kinase inhibitor 65 SU# [003] 65 Gleevec imatinib mesylate 65 PREZISTA r 65 Controlled Trial 65 Chronic Myeloid Leukemia CML 65 imatinib mesylate 65 Factor Receptor 65 rilonacept 65 Angiotensin Converting Enzyme 65 metastatic RCC 65 trastuzumab Herceptin ® 65 mu opioid receptor antagonist 65 Etoposide 65 Xelox 65 IV Busulfex 65 Newly Diagnosed 65 Torisel 65 murine monoclonal antibody 65 TEMODAL 65 Vicriviroc 65 Rotigotine 65 HQK 65 Pegloticase 65 eltrombopag 65 adriamycin 65 Silodosin 65 Ramelteon 65 oral rivaroxaban 65 uric acid lowering 65 rHuPH# 65 Placebo Controlled Study 65 Double Blind Randomized 65 Pharmacokinetics 65 AAG geldanamycin analog 65 denileukin diftitox 65 Zevalin R Ibritumomab 65 rhIL 7 65 stage IIIB 65 BANZEL 65 Tarceva TM 65 muscarinic 65 IMA# 65 topoisomerase II inhibitor 65 Interferon alpha 65 Albuferon TM 65 Angiotensin 65 pimozide 65 brostallicin 65 potent CYP#A# inhibitors 65 Colorectal Cancer Patients 65 Dexamethasone 65 dacarbazine DTIC 65 PI3K inhibitor 65 CHOP chemotherapy 65 Advanced Solid Tumors 65 Rivaroxaban 65 taxane 65 SPIRIVA ® 65 Zorbtive TM 65 TNFa 65 tenofovir emtricitabine 65 CCX# B 65 GSK # 65 ORENCIA R 65 GnRH agonist 65 KSP inhibitor 65 Sitagliptin 65 long acting muscarinic 65 Angiogenic 65 Neuvenge 65 Aplidin 65 soluble tumor necrosis 65 non nucleoside 65 diarrhea predominant irritable 65 paclitaxel Taxol R 65 Tesamorelin 65 pegylated interferon alpha 65 talabostat 65 boosted protease inhibitor 65 Infected Patients 65 small molecule tyrosine 65 Treatment Naive Patients 65 MYCAMINE 65 PROMACTA 65 ISIS # 65 Follicular Lymphoma 65 capecitabine Xeloda 65 Bicalutamide 65 relapsing multiple sclerosis 65 Trodusquemine MSI 65 Patients Treated 65 Xyfid TM 65 Adjunctive Therapy 65 relapsed refractory multiple myeloma 65 EGFR inhibitor 65 flavopiridol 65 nitazoxanide 65 Malignant Melanoma 65 tiotropium bromide 65 ASCO GI 65 Linagliptin 65 tenofovir disoproxil fumarate Viread 65 Cetuximab 65 Rheumatoid Arthritis Patients 65 ZYVOX 65 AVE# 65 tiuxetan 65 novel topoisomerase 65 liposome encapsulated 65 peptidic compound 65 Cannabinoid 65 JAK inhibitor 65 IgG1 monoclonal antibody 65 ACTEMRA TM 65 Pradefovir 65 somatostatin analog 65 insulin glulisine 65 Faropenem 65 Prospective Randomized 65 antiinflammatory 65 BRAF inhibitor 65 R lenalidomide 65 daptomycin 65 Thrombin 65 CGRP 65 Aldosterone 65 cis retinoic acid 65 enzyme inhibitors 65 KNS # 65 Alinia 65 immunostimulatory 65 pemetrexed 65 Aviptadil 65 FOLPI 65 Abstract Number 65 oral JAK1 65 calcitonin 65 MDV# 65 Oxaliplatin 65 systemic antifungal 65 paclitaxel Taxol ® 65 Phase Ib Clinical Trial 65 Avastin bevacizumab